Open AccessTestosterone, HIV, and cardiovascular disease risk
Author(s) -
Jelani Grant,
Quentin Loyd,
Claudia Martinez
Publication year - 2021
Publication title -
cardiovascular endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.498
H-Index - 8
ISSN - 2574-0954
DOI - 10.1097/xce.0000000000000236
Subject(s) - testosterone (patch) , medicine , disease , testosterone replacement , human immunodeficiency virus (hiv) , population , cardiovascular health , gerontology , androgen , environmental health , family medicine , hormone
There has been a recent increase in the use of testosterone supplementation among young adults in the United States, despite the controversy of testosterone replacement therapy (TRT) and cardiovascular safety. The lower testosterone levels and earlier age of TRT use in persons living with HIV (PLHIV) is of particular relevance for this population because cardiovascular disease (CVD) comorbidities are known to be increased among PLHIV. There is very limited data on TRT in PLHIV, as such, in this article, we sought to compile current evidence regarding the diagnosis and management of testosterone deficiency and its link to CVD risk including among PLHIV.